Digestive Diseases and Sciences

, Volume 59, Issue 10, pp 2580–2587 | Cite as

High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years

  • Li-Fu Kuo
  • Chuan-Mo Lee
  • Chao-Hung Hung
  • Jing-Houng Wang
  • Tsung-Hui Hu
  • Sheng-Nan Lu
  • Chi-Sin Changchien
  • Chien-Hung Chen
Original Article

Abstract

Background

A recent study showed that chronic hepatitis B virus (HBV) carriers with nucleos(t)ide analogue (NA)-induced hepatitis B antigen (HBeAg) seroconversion occurring before the age of 30 years have a higher risk of HBV reactivation.

Aim

To compare the risk of HBV reactivation and HBeAg seroreversion between patients with spontaneous and NA-induced HBeAg seroconversion.

Methods

A total of 135 and 251 non-cirrhotic patients with NA-induced and spontaneous HBeAg seroconversion, respectively, were analyzed.

Results

NA-induced HBeAg seroconverters faced higher risks of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconverters (P < 0.001). In spontaneous HBeAg seroconverters, age at HBeAg seroconversion, sex, HBV DNA levels before HBeAg seroconversion, HBV genotype C, and pre-S deletions were independent predictors of HBV reactivation. In NA-induced HBeAg seroconverters, only age at baseline was an independent predictor of HBV reactivation. To determine whether the difference in the incidence of HBV reactivation or HBeAg seroreversion between two groups was age-specific, we analyzed these patients according to their age at HBeAg seroconversion (20–29, 30–39, and ≥40 years). Our data showed that NA-induced HBeAg seroconversion was an independent predictor of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconversion in patients older than 40 years at HBeAg seroconversion, but not in patients between 20–29 and 30–39 years of age.

Conclusions

NA-induced HBeAg seroconverters are associated with higher risks of HBV reactivation and HBeAg seroreversion compared to spontaneous HBeAg seroconverters, especially in patients who are older than 40 years at HBeAg seroconversion.

Keywords

Nucleos(t)ide analogue Hepatitis B virus HBeAg seroconversion HBeAg seroreversion HBV reactivation 

Abbreviations

ALT

Alanine aminotransferase

AFP

Alpha-fetoprotein

BCP

Basal core promoter

CHB

Chronic hepatitis B

HBeAg

Hepatitis B e antigen

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

NAs

Nucleos(t)ide analogues

PCR

Polymerase chain reaction

ULN

Upper limit of normal

Notes

Acknowledgments

This study was supported by grants NSC 101-2314-B-182A-026 from the National Science Council.

Conflict of interest

None.

References

  1. 1.
    Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403.PubMedCrossRefGoogle Scholar
  2. 2.
    Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–1150.PubMedCrossRefGoogle Scholar
  4. 4.
    Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174.PubMedCrossRefGoogle Scholar
  5. 5.
    Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527.PubMedCrossRefGoogle Scholar
  6. 6.
    Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–834.PubMedCrossRefGoogle Scholar
  7. 7.
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–624.PubMedCrossRefGoogle Scholar
  8. 8.
    Brunetto MR, Giarin M, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B virus in course of chronic hepatitis. Proc Natl Acad Sci USA. 1991;88:4186–4190.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Naoumov NV, Schneider R, Grötzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology. 1992;102:538–543.PubMedGoogle Scholar
  10. 10.
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806.PubMedCrossRefGoogle Scholar
  11. 11.
    Lee CM, Ong GY, Lu SN, Changchien CS, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669–674.PubMedCrossRefGoogle Scholar
  12. 12.
    Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Proposition, challenges, and future directions. Hepatol Int. 2010;4:386–395.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 2003;52:420–424.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Kuo YH, Chen CH, Wang JH, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis. 2012;206:1521–1531.PubMedCrossRefGoogle Scholar
  16. 16.
    Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Chen CH, Hung CH, Lee CM, et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133:1466–1474.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol. 2005;43:6000–6006.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Chen CH, Lee CM, Lu SN, et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol. 2006;44:76–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen CH, Lee CM, Hung CH, et al. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int. 2007;27:806–815.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee CM, Chen CH, Lu SN, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol. 2003;1:95–101.Google Scholar
  22. 22.
    Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940–1946.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–421.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for posttreatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003;52:1779–1783.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–1465.PubMedCrossRefGoogle Scholar
  26. 26.
    Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756–1762.PubMedCrossRefGoogle Scholar
  27. 27.
    Chen CH, Lee CM, Wang JH, et al. Combination and evolution of HBV mutant strains in HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int. 2013;7:477–488.CrossRefGoogle Scholar
  28. 28.
    Yeh CT, Hsu CW, Chen YH, et al. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol. 2009;45:114–118.PubMedCrossRefGoogle Scholar
  29. 29.
    Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273.PubMedCrossRefGoogle Scholar
  30. 30.
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.PubMedCrossRefGoogle Scholar
  31. 31.
    Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Li-Fu Kuo
    • 1
  • Chuan-Mo Lee
    • 1
  • Chao-Hung Hung
    • 1
  • Jing-Houng Wang
    • 1
  • Tsung-Hui Hu
    • 1
  • Sheng-Nan Lu
    • 1
  • Chi-Sin Changchien
    • 1
  • Chien-Hung Chen
    • 1
  1. 1.Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung and School of Medicine, College of MedicineChang Gung University, TaoyuanKaohsiungTaiwan

Personalised recommendations